View more prostate cancer trials »

Recall Study- Symptoms of Lower Tract Dysfunction Research Network (LURN)  
Aims: To provide valuable information to researchers about patients' experiences with urinary symptoms and how the symptoms are managed by the urologist.  We want to understand how long, and how accurately, people can remember their bladder problems by using online surveys. The ultimate goal of the study is to collect information that will improve the care and treatment for people with urinary symptoms. 
Diagnosis: Men with moderately severe or severe bladder problems
Principal Investigator: Brian Helfand, MD, PhD
IRB Approval Number: EH17-151
Sponsor: National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact: Study Coordinator, Pooja Talaty at 847.503.4280
Open to Enrollment: Yes

Neuroimaging and Sensory Testing Study- Symptoms of Lower Tract Dysfunction Research Network (LURN)  
Aims: To better understand how the brain and sensory nerves contribute to bothersome urinary symptoms and overactive bladder by comparing persons who have problems to those who do not (control group).  Participants will undergo a brain MRI scan, a hearing test, and a thumnail test (use of a device to put pressure on the thumb) at Northwestern Memorial Hospital in downtown Chicago. These  tests will produce information on how different parts of the brain, and sensitivity changes in the nervous system, might contribute to bladder problems with the ultimate goal of improving treatment for these conditions. 
Diagnosis: Men with overactive bladder and, to serve as controls, men who do not have urinary problems
Principal Investigator: Brian Helfand, MD, PhD
IRB Approval Number: EH15-143
Sponsor: National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact: Study Coordinator, Pooja Talaty at 847.503.4280
Open to Enrollment: Yes

Clinical Validation of a Urine-Based Assay with Genomic and Epigenomic Markers for Predicting Recurrence during Non-Muscle Invasive Bladder Cancer Surveillance
Aims: To determine the ability of a experimental urine test to detect recurrence in patients with previously-diagnosed bladder cancer.  The sponsor hopes that this new test will reduce the need for cystoscopy in patients who are unlikely to have a recurrence and improve compliance in patients who need to have a cystoscopy.
Diagnosis: Men and women with a history of non-muscle invasive bladder cancer
Principal Investigator: Brian Helfand, MD, PhD
IRB Approval Number: EH16-009
Sponsor: Genomic Health, Inc.
Contact: Study Coordinator, Jasmine Nero at 847.503.3087 
Open to Enrollment: Yes

3-Dimensional Transrectal Ultrasound for Prostate Cancer Diagnosis and Surveillance
Aims: To evaluate the impact of using a 3-dimensional transrectal ultrasound for diagnosis and surveillance of prostate cancer. Before the Food and Drug Administration (FDA) approved 3-D ultrasounds, all prostate biopsies were performed using 2-dimensional images. The 3-D technology potentially allows for better visualization to increase accuracy of needle placement when sampling different parts of the prostate. The study involves access to your medical record and does not include any additional procedures.
Diagnosis: Men having a 3-D prostate biopsy
Principal Investigator: Michael McGuire, MD
IRB Approval Number: EH10-379
Sponsor: NorthShore University HealthSystem
Contact: Study Coordinator, Jackie Petkewicz at 847.503.4282
Open to Enrollment: Yes

ENACT: A Randomized Study of Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance
Aims: To see if the drug enzalutamide, an approved treatment for advanced prostate cancer, can delay the progression of early stage prostate cancer. To learn what is best, we need to compare patients taking enzalutamide to patients on active surveillance. In active surveillance men with low grade, low volume prostate cancer are monitored with periodic blood tests and biopsies.  They only have treatment (surgery, radiation) if or when the cancer worsens.  In the sutdy, a computer will randomly place participants in either the enzalutamide or active surveillance group. Patients in the enzalutamide group will be followed with the same tests and biopsies as those in the active surveillance group. 
Diagnosis: Men diagnosed with low or intermediate risk prostate cancer within the last 6 months
Principal Investigator: Brian Helfand, MD, PhD
IRB Approval Number: EH16-237
Sponsor: Astellas Pharma Global Development Inc.
Contact: Study Coordinator, Jasmine Nero at 847.503.3087
Open to Enrollment: Yes

Compliance and Outcomes with Penile Rehabilitation in Men after Prostate Cancer Treatment
Aims: To determine the impact of sexual function rehabilitation on quality of life in men who have undergone prostate cancer treatment with either surgery or radiation therapy. Treatment compliance and satisfaction will be measured. The study involves periodic questionnaires.
Diagnosis: Men with sexual dysfunction following prostate cancer treatment 
Principal Investigator: Jeffrey Albaugh, PhD, APRN
IRB Approval Number: EH13-049
Sponsor: NorthShore University HealthSystem
Contact: Nurse Navigator, Martha McCurdy at 847.503.4245 or Study Coordinator, Nick Kirwen at 847.503.4281
Open to Enrollment: Yes

REASSURE ME: Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination thru Engagement in Mindfulness Education
Aims: To examine an 8-week health promotion and lifestyle wellness program intended to improve the quality of life in men (and their partners, if applicable) diagnosed with prostate cancer who are being followed by active surveillance.  The study will allow health care professionals to learn more about how these different health and wellness interventions work and if they should become a part of regular supportive care services for patients.
Diagnosis: Men with prostate cancer being followed by active surveillance who were diagnsosed in the last year 
Principal Investigator: Kristian Novakovic, MD
IRB Approval Number: EH15-124
Sponsor: NorthShore University HealthSystem
Contact: Study Coordinator, Nick Kirwen at 847.503.4281
Open to Enrollment: Yes